Medicenna Therapeutics Insider Trading

Medicenna Therapeutics is a Canadian biotechnology company in the clinical stage of development, focused on immunotherapy treatments for cancer, inflammation, and immune-mediated diseases. The company develops a class of biological agents it calls Superkines and empowered Superkines. Its lead clinical program is bizaxofusp, an interleukin-4 targeted therapy being developed for recurrent glioblastoma. The company is also developing MDNA11, an interleukin-2 based therapy designed to activate anti-cancer immune cells while limiting the activity of immunosuppressive regulatory T cells, and MDNA113, a bifunctional molecule combining anti-PD-1 and interleukin-2 activity that is designed to target tumors. In addition to these programs, Medicenna has preclinical candidates in other disease areas. MDNA209 is an interleukin-2 and interleukin-15 antagonist being studied for autoimmune conditions including multiple sclerosis and graft versus host disease. MDNA413 is an interleukin-4 and interleukin-13 antagonist aimed at inflammatory conditions such as asthma, atopic dermatitis, and other allergic diseases. The company is headquartered in Toronto, Canada.